ReutersRoche’s first-quarter 2022 sales rose 10 percent on strong U.S. demand for rapid COVID-19 antigen tests and specialty drugs but the Swiss drugmaker reaffirmed that a drop in pandemic-related demand would put the brakes on growth.
ReutersThe Biden administration faces an April 18 deadline on whether to extend or end a mandate requiring travelers to wear masks on airplanes, trains and in transit hubs.
The U.S. Food and Drug Administration on March 2 warned people against the use of unauthorized versions of certain COVID-19 rapid antigen tests currently being marketed in the United States.
The Omicron variant can survive longer than earlier versions of the coronavirus on plastic surfaces and human skin, Japanese researchers found in laboratory tests. Additionally, new research shows users of rapid antigen tests to detect COVID-19 should swab their nostrils as directed by the manufacturer and not swab the throat or cheek instead.
The U.S. Centers for Disease Control and Prevention (CDC) on January 4 backed the agency’s week-old guidance for people seeking to end their COVID-19 isolation at five days, adding they could take a rapid antigen test if they want to and can access one, but is not requiring that.
The U.S. health regulator granted emergency use authorization for Abbott Laboratories’ molecular test to detect and distinguish the coronavirus and two types of flu viruses with a single test.
The U.S. Food and Drug Administration authorized emergency use of the first over-the-counter Covid-19 antigen test, which can be used at home.
Swiss drugmaker Roche plans to boost rapid Covid-19 antigen test production to hundreds of millions monthly – including possible saliva tests – Chief Executive Severin Schwan said, acknowledging the fierceness of the pandemic’s second wave took him by surprise.